Effects of intraoperative HES130/0.4 on postoperative kidney function :A retrospective cohort study using DPC database.
- Conditions
- Patients who underwent surgery under general anesthesia or regional anesthesia
- Registration Number
- JPRN-UMIN000027896
- Lead Sponsor
- Otsuka Pharmaceutical Factory, Inc.
- Brief Summary
The incidence of any stages of postoperative acute kidney injury (AKI) was not different between HES group and non-HES group (6.2% vs. 5.5%; RR, 1.123; 95%CI, 0.999-1.263; P=0.053). The number of patients who required postoperative renal replacement therapy was significantly smaller in HES group than in non-HES group (0.2% vs. 0.4%; RR, 0.50; 95%CI, 0.28-0.90; P=0.02). The length of postoperative hospital stay was longer in HES group but 30-day mortality was not statistically different. The incidence of any stages of AKI was significantly lower in HES/non-Alb group than Alb/non-HES group. The patients in HES/non-Alb group had significantly shorter length of hospital stay and significantly low 30-day mortality than the patients in Alb/non-HES group.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50000
Not provided
(1)Patients who underwent dialysis treatment or end stage kidney disease (eGFR<15mL/min/1.73m2) before surgery (2)Patients who received dextran or HES70/0.5 (3)Patients who received HES130/0.4 or albumin or blood products during the period between 7 days before surgery and the day of surgery (4)Patients who died within 2 days after surgery (5)Patients who underwent multiple surgeries (during the period of 30 days before and 30 days after the surgery) (6)Patients who received HES130/0.4 only before and/or after surgery on the day of surgery
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method